MedTrace Logo

Secondary Prognostic Index in RefrActory Lymphoma

NCT04804865 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2021-03-23

No results posted yet for this study

Summary

60% of patients with diffuse large B cell lymphoma are healed after first-line treatment which whatever the age. For the remaining 40% of patients (relapses and primary refractories):

* 38% of patients will be cured with a 2nd line including an autologous haematopoietic cell transplantation for those under 65 years.
* for older patients who are not eligible for a autograft: only 70% of patients will be able to receive 2nd line treatment with rates response less than 50%.
* the survival rate in patients receiving 3rd line treatment or more is 15% at 2 years. Actually, no standard of chemotherapy is offered to relapsed or refractory patients after 2 therapeutic lines. Subsequent lines lead to hospitalizations for infectious complications or transfusions without clear clinical benefit with often an impacted quality of life.

Palliative care is rarely offered as part of the treatment overall load.

Conditions

Interventions

OTHER

prognostic assessment

determination of a prognostic score with 3 clinical and 5 biological parameters.

Sponsors & Collaborators

  • Weprom

    lead OTHER

Principal Investigators

  • Katell LE DU, MD · Weprom

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04804865 on ClinicalTrials.gov